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Abstract
HIV-1 entry into host cells is mediated by the sequential binding of the envelope glycoprotein gp120 to CD4 and a
chemokine receptor. Antibodies binding to epitopes overlapping the CD4-binding site on gp120 are potent inhibitors of
HIV entry, such as the llama heavy chain antibody fragment VHH D7, which has cross-clade neutralizing properties and
competes with CD4 and mAb b12 for high affinity binding to gp120. We report the crystal structure of the D7 VHH at 1.5 A ˚
resolution, which reveals the molecular details of the complementarity determining regions (CDR) and substantial flexibility
of CDR3 that could facilitate an induced fit interaction with gp120. Structural comparison of CDRs from other CD4 binding
site antibodies suggests diverse modes of interaction. Mutational analysis identified CDR3 as a key component of gp120
interaction as determined by surface plasmon resonance. A decrease in affinity is directly coupled to the neutralization
efficiency since mutations that decrease gp120 interaction increase the IC50 required for HIV-1 IIIB neutralization. Thus the
structural study identifies the long CDR3 of D7 as the key determinant of interaction and HIV-1 neutralization. Furthermore,
our data confirm that the structural plasticity of gp120 can accommodate multiple modes of antibody binding within the
CD4 binding site.
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Introduction
The envelope glycoprotein (Env) from the human immunode-
ficiency virus type 1 (HIV-1) forms a heterotrimer composed of the
receptor binding subunit gp120 and the membrane anchored
fusion protein subunit gp41. Entry into host cells is mediated by
gp120 interaction with CD4 that triggers a conformational change
allowing subsequent interaction with cellular coreceptors such as
CCR5 or CXCR4 [1–4]. Together these events trigger a refolding
of gp41 that leads to the fusion of virus and host cell membranes
[5–7]. Env is the target for entry inhibitors [8] and neutralizing
antibodies directed against gp120 and gp41 [9]. A main problem
in HIV-1 vaccine research is the generation of cross-subtype
neutralizing antibodies, which is due to the fact that HIV-1
employs a number of strategies to evade the immune response.
This includes highly variable gp120 regions, a carbohydrate shield
[10] and conformational masking of the receptor binding site [11].
The overall conformational flexibility of gp120 is highlighted by
the differences between the native SIV gp120 core structure [12]
and structures representing the CD4- and antibody-induced
conformations of the HIV-1 gp120 [13–16]. Gp120 structures
are composed of an inner and an outer domain; the inner domain
varies substantially including the refolding of the bridging sheet,
while the outer domain harbouring the CD4 binding site is mostly
conserved except for the refolding of the CD4-binding loop
[12,13]. The conformational flexibility is considered to be the
main obstacle to the development of an HIV-1 vaccine, besides the
sequence variability and the glycan shield. Consequently, only few
broadly neutralizing antibodies have been described to date [17].
MAbs 2F5, 4E10 and Z13 recognize epitopes within the
membrane proximal region of gp41 [18–21], mAb 2G12
recognizes a carbohydrate motif [22,23], b12 interacts within
the CD4 binding site [24,25], HJ16 overlaps with the CD4
binding site [26] and antibodies PG9 and PG16 are specific for the
trimeric Env conformation [27].
The crystal structure of gp120 in complex with b12 revealed the
molecular details including a substantial conserved gp120 surface
overlapping between both the CD4- and b12-bound states [14].
The similarities of both interactions is highlighted by the fact that
b12 employs Tyr
53 to fill the hydrophobic pocket in gp120 that is
otherwise occupied by CD4 Phe
43 [14]. MAb b12 is broadly
neutralizing since it engages gp120 at the same exposed surface in
a similar manner as CD4, albeit it does not require the induction
of further conformational changes [14]. The CD4 binding site is
highly conserved, but nonetheless not all antibodies targeting the
CD4 binding site show broad cross-clade neutralization properties
including F105, M12 and M14 for example [15,28–32]. No
breakthrough has yet been reported regarding the efficient
generation of broadly neutralizing monoclonal antibodies upon
immunization of animals with Env antigens [33,34] except for the
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10482generation of camelid antibodies. Three heavy chain only camelid
specific antibody domains D7, A12 and C8, termed VHH, have
been isolated after immunization with gp120. These antibodies
compete with CD4 and b12 for gp120 interaction and exert
neutralizing activity against primary isolates of subtypes B and C
[35].
Here we describe the crystal structure of the camelid VHH D7
and determine the molecular determinants for HIV-1 Env gp120
interaction. Mutagenesis of selected CDR residues abrogate or
enhance gp120 interaction in vitro and correlate with the
neutralization activity of D7 against the B-clade HIV-1 IIIB thus
providing a molecular model for D7-gp120 reactivity.
Results and Discussion
Structure of the VHH D7
The crystal structure of the llama heavy chain antibody
fragment VHH D7 was solved by molecular replacement and
refined to a resolution of 1.5 A ˚ with an R factor of 16.6% and an
Rfree of 19.4% (table 1). D7 folds into a typical immunoglobulin
domain closely resembling known llama VHH structures [36]
(Figure 1A). It contains two canonical (CDR1 and CDR2) and a
long CDR3 typical for llama VHHs [37] with a non-canonical
CDR conformation [38]. CDR3 is composed of 18 residues (Lys
95
– Tyr
102) (Figure 2). The base of CDR3 is well defined and
stabilized by multiple main chain and side chain interactions
including hydrogen bonds and salt bridges with CDR1 (Ser
31-
Arg
97, Asp
33-Lys
95, Asp
33-Arg
97 and Asp
33-Ser
100F) and CDR2
(Ser
52-Asp
100C and Thr
56-Asp
100C) (Figure 1B). The extensive
inter CDR stabilization suggests a potentially lower flexibility of
the CDRs upon binding to gp120. The CD4 binding site antibody
b12 employs only one polar (Ser
30-Tyr
53) and few hydrophobic
inter heavy chain CDR contacts [14,39]. However, the tip of the
D7 CDR3 (Arg
100 - Ser
100B) is highly mobile evidenced by the lack
of continuous main chain density for three residues, including
Tyr
100A positioned at the apex of CDR3, indicating that
their conformational flexibility might be important for gp120
recognition.
Structural comparison of CD4 binding site antibodies
D7 was shown to interfere with CD4 and b12 binding on gp120
and exerts a decent neutralization profile of primary HIV-1 clade
B and C isolates [35]. Its neutralization capacity is similar to that
of b12, although b12 is more potent and both antibodies neutralize
a different spectrum of viruses [35]. MAb b12 employs only the
heavy chain to interact with gp120, indicating that a heavy chain
only antibody such as the D7 VHH could mimic its interaction with
gp120. All three b12 heavy chain CDRs contact gp120, notably
mostly its outer domain [14]. The overlap between the b12 and
the CD4 buried surfaces are considerable and both modes of
interaction employ aromatic residues to fill a hydrophobic pocket
on gp120 (b12 Tyr
53 of CDR2 and CD4 Phe
43) [13,14]. Three
other crystal structures of CD4 binding site mAbs are known,
namely those of unliganded F105 and m18 Fabs [40,41] and F105
and b13 in complex with gp120 [15]. F105, b13 and m18 interfere
with CD4 binding on gp120, neutralize several HIV-1 strains but
exert lower potency in neutralization of primary isolates as
compared to b12 [15,31,42–44]. The structures of gp120 in
complex with F105 and b13 show that it does not suffice to occupy
the CD4 binding site in order to exert broad neutralizing activity
since the orientation of gp120 recognition is most likely not
compatible with binding to the trimeric Env present on virions
[15].
CD4 binding site antibodies b12, b13, F105 and m18 display a
similar architecture of their CDR3 heavy chains with aromatic
residues positioned at the apex of their CDR3 (Figure 3A). This
feature led originally to the proposal that this class of antibodies
employs aromatic CDR residues to fill the gp120 pocket that is
occupied by Phe
43 in the CD4- bound state [41,45]. Although b12
and b13 point their CDR2 residue Tyr
53 and Tyr
52A, respectively,
towards the CD4 binding pocket [14], mAb F105 employs CDR3
Phe
100A and Tyr
100B within the CD4 binding site [15].
Sequence alignment of D7 with the heavy chain sequences of
b12, b13, F105 and m18 reveals aromatic residues within CDR2
and CDR3 (Figure 2). Comparison of the CDR2 loops shows
Tyr
53 at the apex of F105 CDR2, no aromatic residue at the apex
of m18 CDR2 and Tyr
53 and Tyr
52a at the apex of b12 and b13
CDR2. The CDR2 of D7 contains Trp
52A, which is however not
solvent accessible. Instead D7 Trp
52A is involved in CDR1
stabilization as observed in another VHH structure [36] (Figure 3B).
It is thus unlikely that D7 CDR2 plays a prominent role in gp120
interaction as observed for CDR2 from b12 and b13.
We thus focused our analysis on the CDR3 region as a potential
gp120 interaction site. Part of this loop region is highly mobile in
the absence of ligand and thus suitable for an induced fit
conformation. CDR3 of D7 is tilted 40u towards CDR2 compared
to the orientation of the CDR H2/H3 of the other antibodies,
whereas the apex of CDR3 is also built by an aromatic residue
(Tyr
100A) like in b12 (Trp
100), F105 (Phe
100A and Tyr
100B), b13
Table 1. X-ray data collection and refinement statistics.
Unit cell dimensions
a( A ˚) 37.37
b( A ˚) 62.18
c( A ˚) 62.74
Space group P212121
Wavelength (A ˚)0 . 9 7 4
Resolution (A ˚) 44.0-1.5
Completeness (%) 94.1 (69.7)
Total reflections 150510
Unique reflections 22695
Rmerge 0.05 (0.20)
s 23 (6.5)
Refinement statistics
Resolution range (A ˚) 44.2-1.5
Reflections/test set 22363/1135
R-factor 0.1657 (0.1819)
Rfree 0.1935 (0.2294)
No. of residues 127
No. of water molecules 189
No. of ligand atoms 4 sulfate ions
Average B-factor (A ˚2) 13.39
r.m.s.d. from ideal
Bond lengths (A ˚)0 . 0 0 6
Bond angles (deg.) 1.070
Ramachandran statistics
Most favoured (%) 93.5
Additionally allowed regions (%) 6.5
doi:10.1371/journal.pone.0010482.t001
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PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10482Figure 1. Structure of the llama heavy chain antibody fragment VHH D7. (A) Ribbon representation of D7; the complementarity determining
regions (CDR) are highlighted in yellow (CDR1), orange (CDR2) and salmon (CDR3). The first and last residue of each CDR is shown together with the
side chain of Trp
96 critical for gp120 interaction and neutralization. The dotted line indicates CDR3 residues lacking continuous main chain density for
residues Arg
100 to Ser
100B.( B) A close-up of the CDR interaction network reveals multiple polar interactions between CDR1 and CDR3 as well as CDR2
and CDR3.
doi:10.1371/journal.pone.0010482.g001
Figure 2. Structure based sequence alignment of D7 with VHH A12 and C8 as well as with the VH domains from the neutralizing
antibodies b12, b13, F105 and m18. The residue numbering is according to Chothia [38] and the CDRs are indicated by coloured bars.
doi:10.1371/journal.pone.0010482.g002
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100C) and m18 (Phe
99). Notably, b12 employs a number of
CDR H3 residues to contact gp120 including Trp
100 (Figure 3B).
However, despite the fact of aromatic residues at the tip of all
CDR3 loops, no significant structural homology between the CDR
loops can be observed underlining the differences in mode of
gp120 interaction.
Mutational analysis of D7 binding to gp120
We performed mutational analysis within CDR3 to substantiate
the role of CDR3 in gp120 interaction by determining the affinity
of the D7 mutants in comparison to the wild type using surface
plasmon resonance. Mutagenesis of solvent exposed CDR3
residues Lys
95Ser, Trp
96Ala and Leu
99Ala (Figures 2 and 3A;
table 2) decreased the affinity of D7 to gp120 (IIIB) significantly to
377, 27 and 69 nM, respectively, compared to 2.9 nM of wild type
D7 (table 3). Note that the affinity of D7 to gp120 determined here
is ,30 times lower than the previously reported KD of 0.097 nM
[35]. In contrast, mutagenesis of solvent exposed residues Asp
100C,
Asn
100D and the double mutant Asn
101Tyr Tyr
102Asp (table 2)
enhanced the affinity to 0.84, 0.51 and 0.18 nM (table 3). Notably,
the double mutation at position 101 and 102 to Tyr and Asp
restores the CDR3 sequence of VHH A12 (Figure 2), which has
broader neutralization potency than D7 [35]. Mutagenesis of
Tyr
100A located at the tip of CDR3 (Figure 3A) has no significant
effect on binding (table 3). The moderate increase of affinity by
mutagenesis of Asp
100C and Asn
100D might reflect a decrease of
the rigidity of the loop since loop stabilizing interactions are
affected (table 3 and Figure 1B). This could lead to an improved
induced fit upon gp120 binding facilitated by an increased CDR
flexibility. The positive effect of the double mutation of
Asn
101Tyr
102 on interaction together with their close location
next to Trp
96 and Lys
95 suggest that they affect binding directly.
Finally, the strong decrease in affinity upon mutagenesis of
residues Lys
95, Trp
96 and Leu
99 indicate that these residues make
Figure 3. Comparison of CDR2 and CDR3 from D7, b12, b13, F105 and m18 indicates different modes of gp120 interaction. The Ca
atoms of the heavy chain variable domains (b12 pdb code 2NY7; F105 pdb code 3HI1; b13 pdb code 3IDX; m18 pdb code 2AJ3) were superimposed
and the CDR H2 and H3 are represented in the same orientation. Amino acids are labelled using the one letter code for clarity. (A) All CDR3 loops
expose aromatic residues at their apex. (B) The CDR2 of D7 varies from CDR H2 of b12 indicating a different mode of gp120 interaction. Residues
implicated in gp120 interaction are highlighted in orange.
doi:10.1371/journal.pone.0010482.g003
Table 2. Solvent accessible areas of CDR3 D7 residues.
residue accessible surface area (A ˚ 2)
Lys
95 36.56
Trp
96 136.34
Leu
99 179.13
Tyr
100A 220.36
Asp
100C 47.52
Asn
100D 80.47
Asn
101 80.56
Tyr
102 52.65
doi:10.1371/journal.pone.0010482.t002
Table 3. Binding affinities of D7 wild type and D7 mutants to
gp120 (IIIB).
mutation ka (10
5 M
21 s
21)k d (10
24 s
21)K D (nM)
wildtype 1.5561.15 5.5161.47 2.9160.87
Lys
95RSer 0.1360.10 23.664.90 3776276
Trp
96RAla 1.4660.46 31.3617.1 27.9620.5
Leu
99RAla 0.1460.12 50.0629.1 69.9614.2
Tyr
100ARAla 2.3360.15 3.5960.08 1.5560.07
Asp
100CRAla 2.3660.13 1.9960.38 0.8460.12
Asn
100DRAla 2.5260.06 1.2860.03 0.5160.02
Asn
101RTyr/Tyr
102RAsp 1.8760.08 0.3360.27 0.1860.15
doi:10.1371/journal.pone.0010482.t003
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is mainly due to an increase of the dissociation rate of the D7
mutants (table 3), which suggests a change of interaction between
the CDR3 loop and gp120 but no major change of loop
conformation. Together, these data implicate that VHH D7
interacts via CDR3 with gp120 and identify Lys
95, Trp
96 and
Leu
99 as key residues for this interaction. Both Lys
95 and Trp
96 at
the beginning of CDR3 are solvent exposed while Leu
99 is part of
the disordered tip of CDR3, which adds to the conformational
freedom of D7 interaction with gp120 (Figure 3A). All three
residues are conserved in VHH A12 suggesting that it will utilize its
CDR3 to contact gp120 in a similar way (Figure 2). A12 differs
only at positions 100D (Tyr instead of Asn) as well as 101 and 102
(Asn, Tyr instead of Tyr, Asp). Further sequence differences that
may account for the higher neutralization potency of A12 include
CDR1 residues (Thr
28 is changed to Ile
28 and His
32 to Tyr
32 in
A12) and CDR2 residue Asn
58 (Asp
58 in A12).
In order to confirm the role of CDR3 and the correlation of
gp120 interaction and neutralization, wild type D7 and mutants
were tested in a TZM-b1 neutralization assay against HIV-1 IIIB.
Comparison of the IC50 values reinforces the importance of
CDR3. Mutations that lead to decreased gp120 interaction,
namely Ala mutations of Lys
95 and Trp
96, showed a 100-fold
increase in IC50, and Leu
99 revealed a 10-fold increase in IC50 as
compared to D7 wild type (table 4). In contrast, mutation of
Tyr
100A and Asp
100C show a modest decrease in the IC50 (table 4)
consistent with a slightly increased affinity for gp120 (table 3). The
largest positive effect was observed for the double mutant
Asn
101Tyr
102, which shows a ,10-fold increase in affinity
(table 3) and a reduction of the IC50 value by a factor of 5
(table 4). This underlines the important role of CDR3 (Figure 4A)
for neutralization of HIV-1. Since the CD4 binding site on gp120
is negatively charged [13] CDR3 could provide some comple-
mentary basic charge for interaction (Figure 4B). Together these
findings indicate that the differences related to CDR3 constitute
an important factor accounting for the broader neutralization
profile of A12 compared to D7 [35] since both CDR1 and CDR2
are almost identical (Figure 2). It is thus possible that C8 employs
different structural principles for gp120 interaction and neutral-
ization [35].
Conclusions
The conformation of the primary receptor binding site of HIV-1
gp120 reveals a hydrophobic pocket which is the target for Phe
43
of the natural receptor CD4 [13] and overlaps with the binding
sites of neutralizing antibodies b12 [14], b13 and F105 [15]. The
structural and mutational data presented here show that D7 does
not expose an aromatic residue at its CDR2 and that Tyr
100A at
the apex of CDR3 does not play a key role in gp120 interaction
and HIV-1 IIIB neutralization. Thus D7 might employ different
structural principles than b12 to interact with gp120. This is
further supported by preliminary results on the D7 interaction
with HIV-1 envelope proteins gp140CN54, gp140UG37, gp120IIIB,
gp120YU2 and its modified variant gp120Ds2, in which an
additional S-S (109-428) bridge was introduced, thus closing the
cavity below the bridging sheet [14]. VHH D7 binds to gp120IIIB,
gp140UG37 and gp120YU2 but is unable to interact with gp120Ds2
strongly indicating that D7 does not bind to the outer domain, as
b12 does (A. Szynol personal communication). This is further
supported by antibody recognition of a gp120 escape mutant.
Whereas gp120 mutation G366E results in impaired binding of
sCD4 and b12, the binding of D7 was not effected (A. McKnight,
personal communication), further corroborating differences in
Table 4. IC50 values of VHH D7 against HIV-1 IIIB in TZM-bl
cells.
IC50 (mg/ml) IC50 (mg/ml) IC50 (mg/ml)
mutation Exp1* Exp2* Average**
wildtype 0.066 0.041 0.054
Lys
95RSer 3.426 2.641 3.0
Trp
96RAla 2.717 2.428 2.6
Leu
99RAla 0.817 0.560 0.69
Tyr
100ARAla 0.028 0.018 0.023
Asp
100CRAla 0.40 0.014 0.027
Asn
100DRAla ND ND ND
Asn
101RTyr/Tyr
102RAsp 0.017 0.005 0.011
*) Experiments were carried out in duplicate wells.
doi:10.1371/journal.pone.0010482.t004
Figure 4. Surface representation of the CDRs. (A) Surface
representation of D7 revealing the gp120 docking interface based on
gp120 binding and HIV-1 neutralization results. The CDRs are coloured
as in figure 1. CDR3 residues affecting gp120 interaction and HIV-1 IIIB
neutralization are indicated in white and residue differences between
D7 and A12 are labelled in black. (B) Electrostatic potential map of the
surface generated by the CDRs.
doi:10.1371/journal.pone.0010482.g004
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96 as
a key residue for gp120 interaction and neutralization its position
and limited extension form the core structure albeit its solvent
exposure (table 4) does not conclusively indicate how it could reach
into the hydrophobic CD4 binding pocket on gp120. Thus CD4
binding site antibodies might be broadly neutralizing without
closely mimicking important molecular details of the CD4-gp120
interaction. Although the structure establishes a firm role for
CDR3 and its flexible anchoring in interaction and neutralization
activity, structural analysis of gp120 in complex with D7 is
required to fully understand the conformational flexibility of both
gp120 and D7 in order to exploit this knowledge for a rational
vaccine design.
Materials and Methods
D7 purification, crystallization and structure solution
S. cerevisiae strain VWk18gal1 (CEN-PK102-3A, MATa, leu2-3,
ura3, gal1::URA3, MAL-8, MAL3, SUC3) was used for the
fermentative production of D7. The VHH D7 gene contains the
following amino acid substitutions compared to wild type D7 [35]
in framework residues Val5Gln, Ala11Val, Ala61Val, Ala68Asp
and Ser79Tyr, which occur naturally in other known VHH
structures [36]. The gene was integrated into the S. cerevisiae
genome in the rDNA locus [46] and grown as described [47]. VHH
D7 was purified from the supernatant using Ni
2+-affinity
chromatography in PBS. A final size exclusion chromatography
was performed on a Superdex 200 (GE Healthcare) in a buffer
containing 20 mM HEPES pH 7, 0.1 M NaCl. VHH D7 was
crystallized using the hanging drop vapor diffusion method at
room temperature. Crystals formed by mixing D7 (at 5 mg/ml)
with an equal volume of 100 mM sodium cacodylate pH 6,
20 mM magnesium acetate, 1.7 M ammonium sulphate and 19%
glycerol. Crystals were flash frozen in liquid nitrogen using 30%
glycerol as cryo-protectant. A native dataset was collected to a
resolution of 1.5 A ˚ at ESRF beam line (Grenoble, France) BM14.
The dataset was processed with MOSFLM [48] and SCALA
[49,50]. The crystals belong to space group P212121 with unit cell
dimensions of a=37.37 A ˚, b=62.18 A ˚, c=62.74 A ˚ containing 1
molecule in the asymmetric unit.
The structure was solved by molecular replacement using the
program PHASER [51] and the VHH structure pdb code 1HCV
as a search model. The initial model was built using ARPWARP
[52] and completed by several cycles of manual rebuilding in
COOT [53] and refinement in REFMAC [54] and PHENIX [55]
to Rwork/Rfree values of 0.1657/0.1935. The final model contains
127 residues, 189 water molecules and 4 sulfates (see table 1). All
molecular graphics figures were generated with PYMOL (W
Delano; http://www.pymol.org/). Coordinates and structure
factors of D7 have been deposited in the Protein Data Bank with
accession number 2xa3.
Mutation of VHH D7 and Surface Plasmon Resonance
analysis of D7 binding to gp120
Mutations of the VHH D7 sequence [35] were generated by
using the quick change mutagenesis kit (Stratagene). The
mutations were verified by sequencing. Wild type and mutant
VHH D7 proteins were expressed in E. coli and purified following
the protocol for wild type D7 purification [35].
Gp120 (IIIB) was coupled covalently to channel 2 of a CM5
chip (GE Healthcare) following the manufacturer’s instructions.
Briefly, the CM5 chip was activated with 50 mL EDC/NHS at a
flow rate of 25 ml/min. Adsorption of 100 ml gp120 was carried
out in a buffer containing 25 mM sodium acetate pH 5.
Deactivation of the surface was achieved with 50 ml diethanol-
amine. Chanel 1 was treated similar but skipping the step of gp120
adsorption. All binding experiments were performed on a Biacore
X (GE Healthcare) in a buffer containing 10 mM HEPES pH 7.5,
100 mM NaCl, 0.05% P20 at a flow rate of 30 ml/min. The
association of 90 ml D7 or D7 mutants at concentrations of 25 and
100 nM was recorded for 3 min followed by a dissociation of
15 min. The CM5 chip was regenerated with a 20 ml pulse of
0.1 M glycine pH 2 at a flow rate of 50 ml. Data were evaluated
with the BiaEvaluation software (GE Healthcare) using simulta-
neous fit of association and dissociation.
HIV-1 neutralization in TZM-bl cells
HIV-1 neutralization in TZM-bl cells was evaluated using an
assay developed previously [56,57,58]. Three-fold serial dilutions
of VHH (starting at 20 mg/ml) were prepared in growth medium
(DMEM containing 10% FCS) in duplicate wells of opaque 96-
well cell culture plates, in a total volume of 50 ml per well.
Approximately 200 TCID50 of virus, in 50 ml of growth medium,
was added to each well, and the plates were subsequently
incubated at 37uC. After 1 hour of incubation, 1 ? 10
4 newly
trypsinized TZM-bl cells in 100 ml of growth medium containing
30 mg/ml of DEAE-dextran (Sigma-Aldrich) were added to each
well. For each plate, six wells containing cells and growth medium
only, and six wells containing virus and cells only, were included.
The neutralization activity of each VHH was assayed in duplicate.
The plates were then incubated at 37uC for 48 hours and
detection of infection of TZM-bl cells was assayed by measuring
luminescence production according to the manufacturer’s instruc-
tions (Promega). Lysis of cells was allowed to occur for 2 minutes
and luminescence (in relative light units; RLU) was then detected
using a GloMax 96 Luminometer (Promega). Neutralization was
measured as the reduction in RLU in test wells compared to virus
control wells after subtraction of background luminescence. The
lowest VHH or antibody concentration required to give 50%
reduction in RLU (IC50) was determined by fitting the data to a
sigmoidal equation using the XLFit 4 software (IDBS).
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